van den Meiracker A H, Man in 't Veld A J, Admiraal P J, Ritsema van Eck H J, Boomsma F, Derkx F H, Schalekamp M A
Department of Internal Medicine 1, University Hospital Dijkzigt, Rotterdam, The Netherlands.
J Hypertens. 1992 Aug;10(8):803-12.
To investigate whether the compensatory rise in renin and plasma angiotensin I in response to repeated angiotensin converting enzyme (ACE) inhibitor treatment results in a partial escape of ACE inhibition over a 24-h dosing interval.
A single-blind placebo-controlled study in two parallel groups of eight hypertensive subjects receiving a once-daily dose of the ACE inhibitor, spirapril, of either 12.5 or 25 mg. Detailed 24-h studies were performed at the end of 2 weeks of placebo, and after the first dose and 2 weeks administration of spirapril.
Twenty-four-hour ambulatory blood pressure was measured invasively. True' angiotensins I and II were measured by radioimmunoassay after high-performance liquid chromatography separation.
Both for the lower and higher doses of spirapril, the time-course of changes of spiraprilat, the active metabolite of spirapril, and ACE activity was similar but the maximal rise in angiotensin I was twofold higher after 2 weeks administration than after the first dose. Angiotensin II after the first dose of spirapril fell rapidly, with lowest values 2 to 4 h after dosing. At the end of dosing interval angiotensin II had returned to values seen under placebo with the 12.5-mg dose, but at the end of the 24-h period it was still suppressed with the 25-mg dose. Compared with these first-dose responses the initial maximal degree of angiotensin II suppression after 2 weeks administration of either dose was similar, but during the subsequent hours the degree of angiotensin II suppression tended to be less with the lower and was significantly less with the higher dose of spirapril. With the lower dose of spirapril responses of 24-h ambulatory blood pressure to the first dose and to 2 weeks of administration were almost superimposable, although blood pressures in the second half of the dosing interval tended to be higher during chronic treatment. With the higher dose the response of nocturnal blood pressure after 2 weeks administration was diminished by 8.8 mmHg systolic and 6.8 mmHg diastolic.
Repeated ACE inhibitor treatment with once-daily spirapril leads to a partial escape of ACE inhibition, as reflected by a shorter duration of angiotensin II suppression. This escape also affects the antihypertensive response in the second half of the dosing interval.
研究反复给予血管紧张素转换酶(ACE)抑制剂治疗后肾素和血浆血管紧张素I的代偿性升高是否会导致在24小时给药间隔内ACE抑制作用出现部分逃逸。
一项单盲、安慰剂对照研究,将8名高血压受试者分为两个平行组,每日服用一次12.5毫克或25毫克的ACE抑制剂螺普利。在安慰剂治疗2周结束时、首次服用螺普利后以及服用2周后进行详细的24小时研究。
采用侵入性测量24小时动态血压。在高效液相色谱分离后,通过放射免疫分析法测量“真实”的血管紧张素I和II。
对于较低剂量和较高剂量的螺普利,螺普利的活性代谢产物螺普利拉和ACE活性的变化时间过程相似,但给药2周后血管紧张素I的最大升高幅度是首次给药后的两倍。首次服用螺普利后血管紧张素II迅速下降,给药后2至4小时达到最低值。在给药间隔结束时,12.5毫克剂量的血管紧张素II已恢复到安慰剂水平,但在24小时结束时,25毫克剂量的血管紧张素II仍受到抑制。与这些首次给药反应相比,两种剂量给药2周后血管紧张素II抑制的初始最大程度相似,但在随后的几个小时内,较低剂量的血管紧张素II抑制程度趋于降低,而较高剂量的螺普利则显著降低。较低剂量的螺普利时,24小时动态血压对首次给药和给药2周的反应几乎重叠,尽管在慢性治疗期间给药间隔后半段的血压往往较高。较高剂量时,给药2周后夜间血压的反应收缩压降低8.8毫米汞柱,舒张压降低6.8毫米汞柱。
每日一次螺普利反复进行ACE抑制剂治疗会导致ACE抑制作用部分逃逸,表现为血管紧张素II抑制持续时间缩短。这种逃逸也会影响给药间隔后半段的降压反应。